Clinical Trial Update: Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Bevacizumab plus Everolimus (RAD001) versus Bevacizumab with Interferon alfa-2a as first-line therapy for renal cell carcinoma; safety …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Afinitor (everolimus)
• Bevacizumab (bevacizumab)
• Roferon-A (interferon alfa-2a)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Carcinoma, Adenocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2014-05-07